Literatur
RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31-45
Sissoko MS, Healy SA, Katile A et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect Dis. 2022;22:377-89
Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411-20
Polhemus ME, Remich SA, Ogutu BR et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One. 2009;4(7):e6465
Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet. 2001;358:1927-34
Wang LT, Pereira LS, Flores-Garcia Y et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity. 2020;53(4):733.e8-744.e8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gillissen, A. Monoklonaler Antikörper zur Behandlung der P.-falciparum-bedingten Malaria. Pneumo News 15, 25–26 (2023). https://doi.org/10.1007/s15033-022-3455-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15033-022-3455-3